专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07470683B2 Tetracyclic compounds 失效
标题翻译：四环化合物
公开(公告)号：US07470683B2
公开(公告)日：2008-12-30
申请号：US11904006
申请日：2007-09-25
申请人： Jean-Louis Peglion , Christophe Poitevin , Mark Millan , Mauricette Brocco
发明人： Jean-Louis Peglion , Christophe Poitevin , Mark Millan , Mauricette Brocco
IPC分类号： C07D498/04 , A61K31/53
CPC分类号： C07D498/04
摘要： Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH═CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.
摘要翻译：式I化合物的反式相对构型：其中：X表示氧原子或NR 2基团，Y表示选自-CH 2 - ， - （CH 2）2 - 和-CH-CH-，R 1和R 2的基团，其中可以相同或不同，各自表示氢原子或选自烷基，环烷基和环烷基烷基的基团，其为外消旋形式或旋光异构体形式，以及其与药学上可接受的酸及其水合物的加成盐。含有该药物的药物可用于治疗涉及多巴胺能系统的中枢神经系统疾病。

2. 发明申请

US20080076765A1 Tetracyclic compounds 失效
标题翻译：四环化合物
公开(公告)号：US20080076765A1
公开(公告)日：2008-03-27
申请号：US11904006
申请日：2007-09-25
申请人： Jean-Louis Peglion , Christophe Poitevin , Mark Millan , Mauricette Brocco
发明人： Jean-Louis Peglion , Christophe Poitevin , Mark Millan , Mauricette Brocco
IPC分类号： A61K31/538 , A61P25/28 , C07D265/34
CPC分类号： C07D498/04
摘要： Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH═CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.
摘要翻译：式I化合物的反式相对构型：其中：X表示氧原子或NR 2基团，Y表示选自-CH 2 - ， - （ CH 2 - ）2 - 和-CH-CH-，R 1和R 2，其可以是相同或不同，各自表示氢原子或选自烷基，环烷基和环烷基烷基的基团，其外消旋形式或旋光异构体形式，以及其与药学上可接受的酸及其水合物的加成盐。含有该药物的药物可用于治疗涉及多巴胺能系统的中枢神经系统疾病。

3. 发明授权

US6107345A Benzocyclobutane compounds 失效
标题翻译：苯并环丁烷化合物
公开(公告)号：US6107345A
公开(公告)日：2000-08-22
申请号：US261803
申请日：1999-03-03
申请人： Jean-Louis Peglion , Aimee Dessinges , Jean-Christophe Harmange , Mark Millan , Adrian Newman-Tancredi , Mauricette Brocco
发明人： Jean-Louis Peglion , Aimee Dessinges , Jean-Christophe Harmange , Mark Millan , Adrian Newman-Tancredi , Mauricette Brocco
IPC分类号： C07D233/50 , A61K31/00 , A61K31/135 , A61K31/33 , A61K31/35 , A61K31/351 , A61K31/38 , A61K31/382 , A61K31/415 , A61K31/4164 , A61K31/4168 , A61K31/445 , A61K31/4465 , A61K31/451 , A61P1/00 , A61P25/18 , A61P25/20 , A61P25/24 , A61P25/30 , A61P43/00 , C07C215/42 , C07C217/58 , C07C217/74 , C07D211/44 , C07D233/48 , C07D263/28 , C07D309/10 , C07D335/02 , C07D345/00 , A61K31/133
CPC分类号： C07D309/10 , C07C215/42 , C07C217/74 , C07D233/48 , C07D263/28 , C07D335/02
摘要： A compound of formula (I): ##STR1## wherein: Z.sub.1, Z.sub.2, Z.sub.3, Z.sub.4, which may be identical or different, represent a group as defined in the description,X represents oxygen, S(O).sub.p, --(CH.sub.2).sub.n -- or --CH.sub.2 --Y--CH.sub.2 -- wherein p, n and Y are as defined in the description,A represents ##STR2## wherein m, R.sub.1, R.sub.2 and G are as defined in the description, their isomers and addition salts thereof with a pharmaceutically-acceptable acid, and medicinal products containing the same are useful in the treatment of diseases like depression, panic attacks, obsessive compulsive disorders, phobias, impulsive disorders, drug abuse or anxiety.
摘要翻译：式（I）的化合物：其中：可以相同或不同的Z 1，Z 2，Z 3，Z 4表示如说明书中所定义的基团，X表示氧，S（O）p， - （CH 2）n - 或-CH 2 -Y-CH 2 - ，其中p，n和Y如说明书中所定义，A表示其中m，R 1，R 2和G如说明书中所定义，其异构体和加成盐与药学上可接受的酸和含有它们的药用产品可用于治疗抑郁症，恐慌发作，强迫症，恐惧症，冲动性疾病，药物滥用或焦虑症等疾病。

4. 发明授权

US06420413B2 Heterocycloalkylbenzocyclobutane and heteroarylbenzocyclobutane compounds 失效
标题翻译：杂环烷基苯并环丁烷和杂芳基苯并环丁烷化合物
公开(公告)号：US06420413B2
公开(公告)日：2002-07-16
申请号：US09833827
申请日：2001-04-12
申请人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Françoise Lejeune , Mauricette Brocco
发明人： Jean-Louis Peglion , Aimée Dessinges , Bertrand Goument , Mark Millan , Françoise Lejeune , Mauricette Brocco
IPC分类号： C07D20970
CPC分类号： C07D407/12 , C07C215/42 , C07D209/16 , C07D209/40 , C07D307/93 , C07D317/70 , C07D319/14 , C07D333/78
摘要： A compound selected from those of formula (I): wherein: denotes single bond or double bond, n is integer from 1 to 6 inclusive, R1, and R2 represent a group selected from hydrogen, linear or branched (C1-C6)-alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, X represents a group selected from —CH═CH—, oxygen, S(O)m wherein m is integer from 0 to 2 inclusive, and NR3 wherein R3 represents a group as defined in the description, Y represents CH or CH2 depending on whether denotes single bond or double bond, or may have the additional meaning of oxygen when X represents oxygen, T represents monocyclic or polycyclic (C3-C10)cycloalkyl optionally containing within the ring system oxygen, selenium, S(O)p, NR3, or SiR4R5 wherein p, R3, R4, and R5 are as defined in the description, its isomers and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful in the treatment of CNS disorders.
摘要翻译：选自式（I）的化合物：其中：表示单键或双键，n为1〜6的整数，R1和R2表示选自氢，直链或支链（C1-C6） - 烷基，芳基，芳基烷基，环烷基，环烷基烷基，烯基，炔基，杂环烷基，杂环烷基烷基，杂芳基和杂芳基烷基，X表示选自-CH = CH-，氧，S（O）m的基团，其中m为0至2的整数和NR 3，其中R 3表示说明书中定义的基团，Y表示CH或CH 2，取决于是单键或双键，或当X表示氧时，可以具有氧的额外含义，T表示单环或多环（C 3 -C 10 ）环烷基，其任选地在环体系内含有氧，硒，S（O）p，NR 3或SiR 4 R 5，其中p，R 3，R 4和R 5如说明书中所定义，其异构体及其加成盐与药学上可接受的酸或碱，以及含有其的药物可用于治疗CNS疾病。

5. 发明授权

US5780474A 3-(piperid-4-yl)-1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds 失效
标题翻译： 3-（哌啶-4-基）-1,2-苯并异恶唑和3-（哌嗪-4-基）-1,2-苯并异恶唑化合物
公开(公告)号：US5780474A
公开(公告)日：1998-07-14
申请号：US868116
申请日：1997-06-03
申请人： Jean-Louis Peglion , Mark Millan , Mauricette Brocco , Valerie Audinot
发明人： Jean-Louis Peglion , Mark Millan , Mauricette Brocco , Valerie Audinot
IPC分类号： A61K31/445 , A61K31/495 , A61P25/18 , A61P25/20 , A61P43/00 , C07D413/12 , C07D413/14 , A61K31/44
CPC分类号： C07D413/12 , C07D413/14
摘要： Compounds of formula: ##STR1## wherein: A, m, n, E and Y are as defined in the description, the optical isomers thereof and the physiologically-tolerable salts thereof. These compounds, their optical isomers and their physiologically-tolerable salts, can be used as medicaments in the treatment of psychotic disorders, anxio-depressive disorders, and aggressiveness.
摘要翻译：式：其中：A，m，n，E和Y如说明书中所定义，其光学异构体及其生理上可容忍的盐。这些化合物，它们的光学异构体及其生理上可耐受的盐可以用作治疗精神病，焦虑抑郁症和侵略性的药物。

6. 发明授权

US06486171B2 Piperidine compounds 失效
标题翻译：哌啶化合物
公开(公告)号：US06486171B2
公开(公告)日：2002-11-26
申请号：US10105171
申请日：2002-03-25
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
IPC分类号： C07D47104
CPC分类号： C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, or a group of formula Y (wherein) as defined in the description, n represents an integer from 1 to 6 inclusive, Z represents a single bond, oxygen, or optionally substituted nitrogen, A and Q each represent CH or nitrogen, it being understood that A or Q must be N and the other CH, M, together with a carbon of the phenyl to which it is bonded, represents thienyl, furyl, pyrrolyl, or oxopyrrolyl, its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same, which are useful in the treatment of some CNS disorders.
摘要翻译：选自式（I）的化合物：其中：W表示任选取代的萘基，或如说明书中所定义的式Y（其中）的基团，n表示1至6的整数，Z表示单键，氧或任选取代的氮，A和Q各自表示CH或氮，应理解A或Q必须为N，另一个CH，M与其所键合的苯基的碳一起代表噻吩基，呋喃基，吡咯基或氧代吡咯基，其异构体及其药学上可接受的酸或碱加成盐，以及含有它们的药物，其可用于治疗一些CNS障碍。

7. 发明授权

US06399616B1 Pyridine compounds 失效
标题翻译：吡啶化合物
公开(公告)号：US06399616B1
公开(公告)日：2002-06-04
申请号：US09641777
申请日：2000-08-18
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Mark Millan , Anne Dekeyne
IPC分类号： A61K31496
CPC分类号： C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound selected from those of formula (I): wherein: W represents optionally substituted naphthyl, n represents an integer from 2 to 3 inclusive, Z represents a single bond, A represents nitrogen, Q represents nitrogen, M, together with the carbon of pyridyl to which it is bonded, represents thieno, furo, pyrrolo or oxopyrrolo, Its optical isomers and pharmaceutically-acceptable acid or base additional salts thereof, and Medicinal products containing the same which are useful in the treatment of CNS disorders. It being understood that “aryl” is phenyl, naphthyl, dihydronaphthyl, or tetrahydronaphthyl.
摘要翻译：选自式（I）的化合物：其中：W表示任选取代的萘基，n表示2〜3的整数，Z表示单键，A表示氮，Q表示氮，M表示与吡咯基，吡咯基或氧吡咯，其光学异构体和药学上可接受的酸或碱的另外的盐，和含有它们的可用于治疗CNS病症的药物。可以理解的是“ 芳基“是苯基，萘基，二氢萘基或四氢萘基。

8. 发明授权

US06903103B2 Linear cyclic ureas 失效
标题翻译：线性循环脲
公开(公告)号：US06903103B2
公开(公告)日：2005-06-07
申请号：US10369860
申请日：2003-02-20
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D417/14 , A61K31/00 , A61K31/437 , A61K31/4427 , A61K31/443 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/551 , A61P3/06 , A61P3/10 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P43/00 , C07D209/08 , C07D211/00 , C07D211/26 , C07D211/58 , C07D401/06 , C07D401/12 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/06 , C07D471/04 , C07D491/04 , C07D401/04 , C07D401/08 , C07D403/04
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): wherein: X represents carbonyl, sulphonyl or sulphoxide, G1, G2 and G3 are as defined in the description, T represents a fused phenyl group or a fused pyridyl group, R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, R2a and R2b, which are the same or different, are as defined in the description, R3 represents aryl or heteroaryl-A as defined in the description, each of which groups may optionally be substituted, Y represents aryloxy, heteroaryloxy or heteroaryl-B as defined in the description, each of which groups may optionally be substituted, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：V表示单键或亚烷基链，M表示单键或亚烷基链，A和E各自表示氮或CH，但两个基团A或E中的至少一个表示氮，W表示式（i），（ii）或（iii）的基团：其中：X表示羰基，磺酰基或亚砜，G 1，G 2和 G 3如说明书中所定义，T表示稠合的苯基或稠合的吡啶基，R 1表示直链或支链的C 1（C 1 H 3）其中烷基部分是直链或烷基，其中烷基部分是直链或直链或支链烷基，分支的R 2a和R 2b相同或不同，如说明书中所定义，R 3表示芳基或杂芳基 - 如在说明书中所定义的A，每个基团可以任选被取代，Y代表描述中定义的芳氧基，杂芳氧基或杂芳基-B，每个 h基团可任选被取代，其异构体，其水合物，其溶剂合物及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。

9. 发明授权

US06566364B2 Linear or cyclic ureas 失效
标题翻译：线性或环状脲
公开(公告)号：US06566364B2
公开(公告)日：2003-05-20
申请号：US09751716
申请日：2000-12-29
申请人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
发明人： Jean-Louis Peglion , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Marie-Pierre Bourguignon , Catherine Thollon
IPC分类号： C07D40112
CPC分类号： C07D401/06 , C07D209/08 , C07D211/26 , C07D211/58 , C07D401/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D417/06 , C07D471/04 , C07D491/04
摘要： Compound of formula (I): wherein: V represents a single bond or an alkylene chain, M represents a single bond or an alkylene chain, A and E each represents nitrogen or CH, but at least one of the two groups A or E represents nitrogen, W represents a group of formula (i), (ii) or (iii): Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）的化合物：其中：V表示单键或亚烷基链，M表示单键或亚烷基链，A和E各自表示氮或CH，但两个基团A或E中的至少一个表示氮，W表示式（i），（ii）或（iii）的基团：含有该基团的药物，其可用于治疗已知内皮功能障碍的疾病或病理状况。

10. 发明授权

US06323217B2 Piperidine-4 sulphonamide compounds 失效
标题翻译：哌啶-4-磺酰胺化合物
公开(公告)号：US06323217B2
公开(公告)日：2001-11-27
申请号：US09772569
申请日：2001-01-30
申请人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
发明人： Jean-Louis Peglion , Aimée Dessinges , Christophe Poitevin , Jean-Paul Vilaine , Nicole Villeneuve , Catherine Thollon , Marie-Pierre Bourguignon
IPC分类号： A61K314725
CPC分类号： C07D401/12 , C07D405/06 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D495/04
摘要： A compound of formula (I): wherein: R1 represents hydrogen or alkyl, R2a and R2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.
摘要翻译：式（I）化合物：其中：R 1表示氢或烷基，R 2a和R 2b表示选自氢，卤素，烷基，羟基，烷氧基，三卤代烷基，氰基，硝基，氨基，烷基氨基和二烷基氨基的基团，R 3表示氢或羟基，X表示氧或亚甲基，V表示任选不饱和且任选取代的亚烷基链，U表示键或亚烷基链，W表示选自芳基和杂芳基的基团，这些基团中的每一个可任选地被一个或多个更多相同或不同的基团，其异构体，其水合物，其溶剂合物及其与药学上可接受的酸的加成盐。含有该药物的药物可用于治疗已知内皮功能障碍的疾病或病理状况。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式